AZ-AXWAY
3.2.2021 18:24:12 CET | Business Wire | Press release
Axway (Euronext: AXW.PA), a global leader in API Management, is building on its elite technology alliance with Amazon Web Services (AWS), joining the AWS ISV Accelerate Program. AWS ISV Accelerate is a co-sell program for AWS Partners who provide software solutions that run on or integrate with AWS. The program helps drive new business and accelerate sales cycles by connecting participating independent software vendors with the AWS Sales organization.
“Axway and AWS continue to build on the strength of its AWS Advanced Technology Partner designation to deliver optimized and integrated solutions on AWS,” said Vince Padua, Axway CTIO. “Through the AWS ISV Accelerate Program, existing and new customers can rely on both companies to align for a more efficient sales process.”
Participation in AWS ISV Accelerate shows that Axway has demonstrated technical expertise on AWS as well as proven customer success. It also means Axway customers benefit from an optimized solution, where Axway teams have direct access to AWS resources.
A recent example of a successful Axway and AWS shared customer is Datlas , an Italian business processing service provider that helps enterprises unlock the value of their data with API-driven business-process outsourcing.
“By deploying Amplify API Management as our core orchestration layer, we gain a single point of control for our microservices, front-end, and third-party systems — cutting management complexity substantially,” said Matteo Settepani, R&D and Software Development Manager at Datlas.
Even during a challenging economic year for Italian companies, Datlas managed to grow its business significantly. Datlas recently completed a proof-of-concept with Axway and AWS Fargate, a serverless compute engine for containers that works with both Amazon Elastic Container Service (Amazon ECS) and Amazon Elastic Kubernetes Service (Amazon EKS).
“AWS teams can now work hand-in-hand with us on a proof-of-concept for the customer,” said Padua. “With AWS ISV Accelerate, we can meet those needs more quickly than ever before.”
This announcement comes shortly after Axway’s recognition as an AWS Partner with AWS Healthcare Competency and AWS Life Sciences Competency designations , a status that recognizes Axway for developing and delivering advanced, reliable solutions for healthcare vendors, payers, and providers.
About Axway
Axway gives heritage IT infrastructure new life, helping more than 11,000 customers worldwide build on what they already have to digitally transform, add new business capabilities, and drive growth. With our Amplify API integration platform — the only open, independent platform for managing and governing APIs across integration patterns, the hybrid cloud, and 3rd-party solutions — we help companies integrate faster, reach new markets, and create brilliant digital experiences. Our MFT and B2B integration solutions have been trusted for 20 years. Axway (Euronext: AXW.PA) employs over 1,800 people in 18 countries. Learn more at axway.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210203005760/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom